Nagata, Jason M. https://orcid.org/0000-0002-6541-0604
Otmar, Christopher D. https://orcid.org/0000-0001-5433-1612
Lee, Christopher M. https://orcid.org/0000-0002-7755-0030
Compte, Emilio J. https://orcid.org/0000-0002-6803-5950
Lavender, Jason M. https://orcid.org/0000-0001-9853-2280
Brown, Tiffany A. https://orcid.org/0000-0002-7349-7228
Forbush, Kelsie T. https://orcid.org/0000-0002-5900-4204
Flentje, Annesa https://orcid.org/0000-0002-1964-4151
Lubensky, Micah E. https://orcid.org/0000-0001-8882-0967
Obedin-Maliver, Juno https://orcid.org/0000-0002-0945-2842
Lunn, Mitchell R. https://orcid.org/0000-0002-0068-0814
Funding for this research was provided by:
Chilean National Agency for Research and Development (11240740)
National Institute of Mental Health (R61MH133710)
Patient-Centered Outcomes Research Institute (PRN‐1501‐26848)
Article History
Received: 21 December 2024
Accepted: 17 March 2025
First Online: 4 April 2025
Declarations
:
: The Institutional Review Boards of Stanford University School of Medicine (#63400), The University of California, San Francisco, and WIRB-Copernicus Group (WCG) approved this study, and oversight was provided by The PRIDE Study’s Research Advisory Committee and Participant Advisory Committee. All procedures performed in this study were in accordance with the ethical standards of the university's Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.
: Not applicable.
: Dr. Obedin-Maliver has received consulting fees from Sage Therapeutics, Ibis Reproductive Health, Folx Health, Inc., Hims and Hers Health, Inc., and Upstream, Inc. Dr. Lunn received consultation fees from Hims and Hers Health, Inc., Folx Health, Inc., Otsuka Pharmaceutical Development and Commercialization, Inc., and the American Dental Association on topics unrelated to this work. None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.